Tiago Medina
Has grant
Tenured Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Tiago Medina is an Assistant Professor at the University of Southern Denmark. His research focuses on immune evasion mechanisms in cancer, therapeutic targets in myeloproliferative neoplasms, and the role of tertiary lymphoid structures in antitumor immunity. Recent publications include studies on the immune landscape of pancreatic ductal adenocarcinomas and the epigenetic regulation in adult gliomas. Dr. Medina's work significantly contributes to understanding the interactions between tumor microenvironments and immune responses.
Recent Grants
Grant: Close
Impact of the immunosenescence on the outcome of COVID-19
Open Date: 2020-10-01
Close Date: 2023-10-01
Grant: Close
Characterization of chromatin and transcriptional landscapes of T cells from gastric adenocarcinoma patients as a tool to discover immunotherapy targets
Open Date: 2020-04-01
Close Date: 2025-04-01
Grant: Close
Impact of epigenetic inhibitors on human CD8 T cells
Open Date: 2019-02-01
Close Date: 2022-02-01
Grant: Close
Epidemiology and genomics of gastric adenocarcinomas in Brazil
Open Date: 2015-08-01
Close Date: 2021-07-01
Articles (12)
Epigenetic therapies facilitate transcription of immunogenic repetitive elements that cull cancer cells through “viral mimicry” responses. Paradoxically, cancer-initiating events also facilitate transcription of repetitive elements. Contributions of repetitive element transcription toward cancer initiation, and the mechanisms by which cancer cells evade lethal viral mimicry responses during tumor initiation remain poorly understood. In this report, we characterize premalignant lesions of the fallopian tube along with syngeneic epithelial ovarian cancer models to explore the earliest events of tumorigenesis following the loss of the p53 tumor suppressor protein. We report that p53 loss permits the transcription of immunogenic repetitive elements and chronic viral mimicry activation that increases cellular tolerance of cytosolic nucleic acids and diminishes cellular immunogenicity. This selection process can be partially attenuated pharmacologically. Altogether, these results reveal that viral mimicry conditioning following p53 loss promotes immune evasion and may represent a pharmacologic target for early cancer interception. Significance: Our landmark discovery of viral mimicry characterized repetitive elements as immunogenic stimuli that cull cancer cells. If expressed repetitive elements cull cancer cells, why does every human cancer express repetitive elements? Our report offers an exciting advancement toward understanding this paradox and how to exploit this mechanism for cancer interception. See related commentary by Murayama and Cañadas, p. 670
Year:
2025
Chimeric antigen receptor (CAR) T-cell therapy is increasingly being adopted as a clinical modality for patients with relapsed/refractory hematologic malignancies. Despite the clinical efficacy of CAR T-cell therapy, a considerable fraction of patients still relapse during the first months following CAR T-cell infusion. The limited CAR T-cell efficiency is thought to relate to epigenetic mechanisms involved in T-cell suppression and dysfunction. In this study, screening of multiple epigenetic inhibitors revealed that targeting polycomb repressive complex 2 (PRC2) consistently induced the development of granzyme B+ effector memory CD8 T cells. Notably, PRC2 inhibition also promoted the long-term persistence of granzyme B+ effector memory 19BBζ CAR T cells and enhanced sustainably their antitumor activity both in vitro and in vivo. Consistent with their long-lasting antitumor activity, PRC2-inhibited 19BBζ CAR T cells did not exhibit signs of exhaustion over time. Furthermore, TCR restimulation along with PRC2 inhibition promoted the differentiation of patient-derived anti-CD19 effector memory CAR T cells with enhanced cytotoxic features and elicited potent antitumor responses. In line with this, the gene signature derived from in-house PRC2-inhibited 19BBζ CAR T cells was enriched in tisagenlecleucel BBζ CAR T-cell therapy responders with large B-cell lymphoma. Collectively, our results demonstrated that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR T cells against hematologic malignancies. Significance: Selective inhibition of PRC2 endows 19BBζ CAR T cells with cytotoxic and effector memory features that are associated with improved antitumor activity and better response to CAR T-cell therapy.
Year:
2025
Chimeric antigen receptor (CAR) T-cell therapy is increasingly being adopted as a clinical modality for patients with relapsed/refractory hematologic malignancies. Despite the clinical efficacy of CAR T-cell therapy, a considerable fraction of patients still relapse during the first months following CAR T-cell infusion. The limited CAR T-cell efficiency is thought to relate to epigenetic mechanisms involved in T-cell suppression and dysfunction. In this study, screening of multiple epigenetic inhibitors revealed that targeting polycomb repressive complex 2 (PRC2) consistently induced the development of granzyme B + effector memory CD8 T cells. Notably, PRC2 inhibition also promoted the long-term persistence of granzyme B + effector memory 19BBζ CAR T cells and enhanced sustainably their antitumor activity both in vitro and in vivo . Consistent with their long-lasting antitumor activity, PRC2-inhibited 19BBζ CAR T cells did not exhibit signs of exhaustion over time. Furthermore, TCR restimulation along with PRC2 inhibition promoted the differentiation of patient-derived anti-CD19 effector memory CAR T cells with enhanced cytotoxic features and elicited potent antitumor responses. In line with this, the gene signature derived from in-house PRC2-inhibited 19BBζ CAR T cells was enriched in tisagenlecleucel BBζ CAR T-cell therapy responders with large B-cell lymphoma. Collectively, our results demonstrated that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR T cells against hematologic malignancies. Significance: Selective inhibition of PRC2 endows 19BBζ CAR T cells with cytotoxic and effector memory features that are associated with improved antitumor activity and better response to CAR T-cell therapy.
Year:
2025
Epigenetic therapies facilitate transcription of immunogenic repetitive elements that cull cancer cells through “viral mimicry” responses. Paradoxically, cancer-initiating events also facilitate transcription of repetitive elements. Contributions of repetitive element transcription toward cancer initiation, and the mechanisms by which cancer cells evade lethal viral mimicry responses during tumor initiation remain poorly understood. In this report, we characterize premalignant lesions of the fallopian tube along with syngeneic epithelial ovarian cancer models to explore the earliest events of tumorigenesis following the loss of the p53 tumor suppressor protein. We report that p53 loss permits the transcription of immunogenic repetitive elements and chronic viral mimicry activation that increases cellular tolerance of cytosolic nucleic acids and diminishes cellular immunogenicity. This selection process can be partially attenuated pharmacologically. Altogether, these results reveal that viral mimicry conditioning following p53 loss promotes immune evasion and may represent a pharmacologic target for early cancer interception. Significance: Our landmark discovery of viral mimicry characterized repetitive elements as immunogenic stimuli that cull cancer cells. If expressed repetitive elements cull cancer cells, why does every human cancer express repetitive elements? Our report offers an exciting advancement toward understanding this paradox and how to exploit this mechanism for cancer interception. See related commentary by Murayama and Cañadas, p. 670
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Collaborators (10)
Ming Sound Tsao
Director (Princess Margaret Cancer Centre Living Biobank Core Facility)
University Health Network
Anjelica Hodgson
University Health Network
Cheryl H. Arrowsmith
Chief Scientist
University of Toronto
Shu Yi Shen
University Health Network
Trevor Shepherd
Professor
Western University
Amit M. Oza
University Health Network
Daniel De Carvalho
Associate Professor
University of Toronto
Katherine B. Chiappinelli
George Washington University
Charles Ishak
Assistant Professor
The University of Texas MD Anderson Cancer Center
Stephanie Gomez
Staff Scientist I
Children's National Health System
Make your next move.
Prepare your application
Review drafts before you send them.